Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Irinotecan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Irinotecan hydrochloride overview
irinotecan hydrochloride is under development for the treatment of recurrent pediatric solid tumors including neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma. The drug candidate is administered by oral route as solution. It is a small molecule and acts by targeting topoisomerase I.
Edison Oncology Holding overview
Edison Oncology Holding is a biopharmaceutical company engaged in the development and commercialization of new therapies targeting the fight against cancer. The company is headquartered in Menlo Park, California, the US.
For a complete picture of Irinotecan hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.